Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer

In patients with RAS wild-type metastatic colorectal cancer (mCRC), an anti-epidermal growth factor receptor (EGFR) monoclonal antibody plus chemotherapy is a standard option for treatment in the first-line setting. Patients who progress while on treatment with anti-EGFR-based therapy can be resista...

Descripción completa

Detalles Bibliográficos
Autores: Cremolini, Chiara, Montagut Viladot, Clara, Ronga, Philippe, Venturini, Filippo, Yamaguchi, Kensei, Stintzing, Sebastian, Sobrero, Alberto
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2023
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:10230/59876
Acceso en línea:http://hdl.handle.net/10230/59876
http://dx.doi.org/10.3389/fonc.2022.946850
Access Level:acceso abierto
Palabra clave:Anti-EGFR
Liquid biopsy
Metastatic colorectal cancer (mCRC)
Rechallenge
Reintroduction
id ES_ca8ac41aeb04d5fc4fbf2e35635f648c
oai_identifier_str oai:recercat.cat:10230/59876
network_acronym_str ES
network_name_str España
repository_id_str
spelling Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancerCremolini, ChiaraMontagut Viladot, ClaraRonga, PhilippeVenturini, FilippoYamaguchi, KenseiStintzing, SebastianSobrero, AlbertoAnti-EGFRLiquid biopsyMetastatic colorectal cancer (mCRC)RechallengeReintroductionIn patients with RAS wild-type metastatic colorectal cancer (mCRC), an anti-epidermal growth factor receptor (EGFR) monoclonal antibody plus chemotherapy is a standard option for treatment in the first-line setting. Patients who progress while on treatment with anti-EGFR-based therapy can be resistant to further anti-EGFR treatment, but evidence suggests that the anti-EGFR-resistant clones decay, thereby opening the potential for rechallenge or reintroduction in later lines of treatment. Results from recent clinical studies have shown that some patients with mCRC who are rechallenged with anti-EGFR monoclonal antibodies exhibit durable responses. While other therapies have demonstrated improved overall survival in chemorefractory mCRC over the past decade, rechallenge with anti-EGFR monoclonal antibodies in later lines of treatment represents a new option that deserves further investigation in clinical trials. In this review, we summarize the molecular rationale for rechallenge or reintroduction in patients with mCRC who have progressed on earlier-line anti-EGFR treatment and examine the current evidence for using liquid biopsy as a method for selecting rechallenge as a therapeutic option. We also provide an overview of published trials and trials in progress in this field, and outline the potential role of rechallenge in the current clinical setting.Frontiers202420242023info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttp://hdl.handle.net/10230/59876http://dx.doi.org/10.3389/fonc.2022.946850reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésFront Oncol. 2023 Feb 2;12:946850© 2023 Cremolini, Montagut, Ronga, Venturini, Yamaguchi, Stintzing and Sobrero. This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY) License (http://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.http://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:recercat.cat:10230/598762026-05-29T05:05:01Z
dc.title.none.fl_str_mv Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer
title Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer
spellingShingle Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer
Cremolini, Chiara
Anti-EGFR
Liquid biopsy
Metastatic colorectal cancer (mCRC)
Rechallenge
Reintroduction
title_short Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer
title_full Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer
title_fullStr Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer
title_full_unstemmed Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer
title_sort Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer
dc.creator.none.fl_str_mv Cremolini, Chiara
Montagut Viladot, Clara
Ronga, Philippe
Venturini, Filippo
Yamaguchi, Kensei
Stintzing, Sebastian
Sobrero, Alberto
author Cremolini, Chiara
author_facet Cremolini, Chiara
Montagut Viladot, Clara
Ronga, Philippe
Venturini, Filippo
Yamaguchi, Kensei
Stintzing, Sebastian
Sobrero, Alberto
author_role author
author2 Montagut Viladot, Clara
Ronga, Philippe
Venturini, Filippo
Yamaguchi, Kensei
Stintzing, Sebastian
Sobrero, Alberto
author2_role author
author
author
author
author
author
dc.subject.none.fl_str_mv Anti-EGFR
Liquid biopsy
Metastatic colorectal cancer (mCRC)
Rechallenge
Reintroduction
topic Anti-EGFR
Liquid biopsy
Metastatic colorectal cancer (mCRC)
Rechallenge
Reintroduction
description In patients with RAS wild-type metastatic colorectal cancer (mCRC), an anti-epidermal growth factor receptor (EGFR) monoclonal antibody plus chemotherapy is a standard option for treatment in the first-line setting. Patients who progress while on treatment with anti-EGFR-based therapy can be resistant to further anti-EGFR treatment, but evidence suggests that the anti-EGFR-resistant clones decay, thereby opening the potential for rechallenge or reintroduction in later lines of treatment. Results from recent clinical studies have shown that some patients with mCRC who are rechallenged with anti-EGFR monoclonal antibodies exhibit durable responses. While other therapies have demonstrated improved overall survival in chemorefractory mCRC over the past decade, rechallenge with anti-EGFR monoclonal antibodies in later lines of treatment represents a new option that deserves further investigation in clinical trials. In this review, we summarize the molecular rationale for rechallenge or reintroduction in patients with mCRC who have progressed on earlier-line anti-EGFR treatment and examine the current evidence for using liquid biopsy as a method for selecting rechallenge as a therapeutic option. We also provide an overview of published trials and trials in progress in this field, and outline the potential role of rechallenge in the current clinical setting.
publishDate 2023
dc.date.none.fl_str_mv 2023
2024
2024
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10230/59876
http://dx.doi.org/10.3389/fonc.2022.946850
url http://hdl.handle.net/10230/59876
http://dx.doi.org/10.3389/fonc.2022.946850
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Front Oncol. 2023 Feb 2;12:946850
dc.rights.none.fl_str_mv http://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Frontiers
publisher.none.fl_str_mv Frontiers
dc.source.none.fl_str_mv reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869419488838942720
score 15,81155

Similares en LA Referencia